Dipeptidyl petidase-IV inhibitor (gemigliptin) inhibits tunicamycin-induced endoplasmic reticulum stress, apoptosis and inflammation in H9c2 cardiomyocytes

Molecular and Cellular Endocrinology

Volumn 392, Issue 1-2, 2014, Pages 1-7

  Hwang, Hwan Jin ^a   Jung, Tae Woo ^a   Ryu, Ja Young ^a   Hong, Ho Cheol ^a   Choi, Hae Yoon ^a   Seo, Ji A ^a   Kim, Sin Gon ^a   Kim, Nan Hee ^a   Choi, Kyung Mook ^a   Choi, Dong Seop ^a   Baik, Sei Hyun ^a   Yoo, Hye Jin ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

Apoptosis; Cardiomyocytes; Dipeptidyl peptidase IV inhibitors; Inflammation

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; C EBP HOMOLOGOUS PROTEIN; ENZYME; GEMIGLIPTIN; GLUCOSE REGULATED PROTEIN 78; INOSITOL REQUIRING ENZYME 1ALPHA; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE P38; NUCLEIC ACID BINDING PROTEIN; PROTEIN KINASE; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; PROTEIN KINASE RNA LIKE ENDOPLASMIC RETICULUM KINASE; STROMAL CELL DERIVED FACTOR 1ALPHA; TUMOR NECROSIS FACTOR ALPHA; TUNICAMYCIN; UNCLASSIFIED DRUG; AUTACOID; CYTOKINE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; IRE1ALPHA PROTEIN, RAT; LC15-0444; MESSENGER RNA; MULTIENZYME COMPLEX; PERK KINASE; PIPERIDONE DERIVATIVE; PROTEIN KINASE R; PROTEIN SERINE THREONINE KINASE; PYRIMIDINE DERIVATIVE; RIBONUCLEASE;

AKT GENE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CARDIOVASCULAR DISEASE; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; ENDOPLASMIC RETICULUM STRESS; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; GENE; HEART MUSCLE CELL; HEART PROTECTION; INFLAMMATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANIMAL; BIOLOGICAL MODEL; CELL LINE; DRUG EFFECTS; ENZYMOLOGY; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; RAT;

ANIMALS; APOPTOSIS; CELL LINE; CYTOKINES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; EIF-2 KINASE; ENDOPLASMIC RETICULUM STRESS; ENDORIBONUCLEASES; INFLAMMATION; INFLAMMATION MEDIATORS; MODELS, BIOLOGICAL; MULTIENZYME COMPLEXES; MYOCYTES, CARDIAC; PHOSPHORYLATION; PIPERIDONES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PYRIMIDINES; RATS; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TUNICAMYCIN;

EID: 84901000873     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2014.04.017     Document Type: Article

References (38)

1. Almdal T., Scharling H., Jensen J.S., Vestergaard H. The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20years of follow-up. Arch. Int. Med. 2004, 164:1422-1426.
2. Bassik M.C., Kampmann M. Knocking out the door to tunicamycin entry. Proc. Natl. Acad. Sci. USA 2011, 108:11731-11732.
3. Blaustein M., Pérez-Munizaga D., Sánchez M.A., Urrutia C., Grande A., Risso G., Srebrow A., Alfaro J., Colman-Lerner A. Modulation of the Akt pathway reveals a novel link with PERK/eIF2alpha, which is relevant during hypoxia. PLoS One 2013, 8:e69668.
4. Deacon C.F. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes. Metab. 2011, 13:7-18.
5. Dong M., Hu N., Hua Y., Xu X., Kandadi M.R., Guo R., Jiang S., Nair S., Hu D., Ren J. Chronic Akt activation attenuated lipopolysaccharide-induced cardiac dysfunction via Akt/GSK3beta-dependent inhibition of apoptosis and ER stress. Biochim. Biophys. Acta 2013, 1832:848-863.
6. dos Santos L., Salles T.A., Arruda-Junior D.F., Campos L.C., Pereira A.C., Barreto A.L., Antonio E.L., Mansur A.J., Tucci P.J., Krieger J.E., Girardi A.C. Circulating dipeptidyl peptidase IV activity correlates with cardiac dysfunction in human and experimental heart failure. Circ. Heart Fail. 2013, 6:1029-1038.
7. Fadini G.P., Agostini C., Sartore S., Avogaro A. Endothelial progenitor cells in the natural history of atherosclerosis. Atherosclerosis 2007, 194:46-54.
8. Fadini G.P., Boscaro E., Albiero M., Menegazzo L., Frison V., de Kreutzenberg S., Agostini C., Tiengo A., Avogaro A. The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha. Diabetes Care 2010, 33:1607-1609.
9. Folli F., Corradi D., Fanti P., Davalli A., Paez A., Giaccari A., Perego C., Muscogiuri G. The role of oxidative stress in the pathogenesis of type 2 diabetes mellitus micro- and macrovascular complications: avenues for a mechanistic-based therapeutic approach. Curr. Diabetes Rev. 2011, 7:313-324.
10. Giacco F., Brownlee M. Oxidative stress and diabetic complications. Circ. Res. 2010, 107:1058-1070.
11. Haunstetter A., Izumo S. Apoptosis: basic mechanisms and implications for cardiovascular disease. Circ. Res. 1998, 82:1111-1129.
12. Hocher B., Sharkovska Y., Mark M., Klein T., Pfab T. The novel DPP-4 inhibitors linagliptin and BI 14361 reduce infarct size after myocardial ischemia/reperfusion in rats. Int. J. Cardiol. 2013, 167:87-93.
13. Hotamisligil G.S. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell 2010, 140:900-917.
14. Ishibashi Y., Matsui T., Ojima A., Nishino Y., Nakashima S., Maeda S., Yamagishi S. Glucagon-like peptide-1 inhibits angiotensin II-induced mesangial cell damage via protein kinase A. Microvasc. Res. 2012, 84:395-398.
15. Johns D.G., Ao Z., Naselsky D., Herold C.L., Maniscalco K., Sarov-Blat L., Steplewski K., Aiyar N., Douglas S.A. Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators. Naunyn Schmiedebergs Arch. Pharmacol. 2004, 370:238-250.
16. Kröller-Schön S., Knorr M., Hausding M., Oelze M., Schuff A., Schell R., Sudowe S., Scholz A., Daub S., Karbach S., Kossmann S., Gori T., Wenzel P., Schulz E., Grabbe S., Klein T., Münzel T., Daiber A. Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition. Cardiovasc. Res. 2012, 96:140-149.
17. Laakso M. Cardiovascular disease in type 2 diabetes: challenge for treatment and prevention. J. Int. Med. 2001, 249:225-235.
18. Lambeir A.M., Durinx C., Scharpé S., De Meester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit. Rev. Clin. Lab. Sci. 2003, 40:209-294.
19. Laudes M., Oberhauser F., Schulte D.M., Schilbach K., Freude S., Bilkovski R., Schulz O., Faust M., Krone W. Dipeptidyl-peptidase 4 and attractin expression is increased in circulating blood monocytes of obese human subjects. Exp. Clin. Endocrinol. Diabetes 2010, 118:473-477.
20. Lim S., Choi S.H., Shin H., Cho B.J., Park H.S., Ahn B.Y., Kang S.M., Yoon J.W., Jang H.C., Kim Y.B., Park K.S. Effect of a dipeptidyl peptidase-IV inhibitor, des-fluoro-sitagliptin, on neointimal formation after balloon injury in rats. PLoS One 2012, 7:e35007.
21. Lonborg J., Vejlstrup N., Kelbæk H., Bøtker H.E., Kim W.Y., Mathiasen A.B., Jørgensen E., Helqvist S., Saunamäk K., Clemmensen P., Holmvang L., Thuesen L., Krusell L.R., Jensen J.S., Køber L., Treiman M., Holst J.J., Engstrøm T. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur. Heart J. 2012, 33:1491-1499.
22. Masuda M., Miyazaki-Anzai S., Levi M., Ting T.C., Miyazaki M. PERK-eIF2alpha-ATF4-CHOP signaling contributes to TNFalpha-induced vascular calcification. J. Am. Heart Assoc. 2013, 2:e000238.
23. Matsubara J., Sugiyama S., Sugamura K., Nakamura T., Fujiwara Y., Akiyama E., Kurokawa H., Nozaki T., Ohba K., Konishi M., Maeda H., Izumiya Y., Kaikita K., Sumida H., Jinnouchi H., Matsui K., Kim-Mitsuyama S., Takeya M., Ogawa H. A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. J. Am. Coll. Cardiol. 2012, 59:265-276.
24. Mu J., Woods J., Zhou Y.P., Roy R.S., Li Z., Zycband E., Feng Y., Zhu L., Li C., Howard A.D., Moller D.E., Thornberry N.A., Zhang B.B. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes 2006, 55:1695-1704.
25. Ohnuma K., Dang N.H., Morimoto C. Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function. Trends Immunol. 2008, 29:295-301.
26. Picatoste B., Ramírez E., Caro-Vadillo A., Iborra C., Egido J., Tuñón J., Lorenzo O. Sitagliptin reduces cardiac apoptosis, hypertrophy and fibrosis primarily by insulin-dependent mechanisms in experimental type-II diabetes. Potential roles of GLP-1 isoforms. PLoS One 2013, 8:e78330.
27. Reinhold D., Bank U., Bühling F., Neubert K., Mattern T., Ulmer A.J., Flad H.D., Ansorge S. Dipeptidyl peptidase IV (CD26) on human lymphocytes. Synthetic inhibitors of and antibodies against dipeptidyl peptidase IV suppress the proliferation of pokeweed mitogen-stimulated peripheral blood mononuclear cells, and IL-2 and IL-6 production. Immunobiology 1993, 188:403-414.
28. Rhee E.J., Lee W.Y., Min K.W., Shivane V.K., Sosale A.R., Jang H.C., Chung C.H., Nam-Goong I.S., Kim J.A., Kim S.W. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Obes. Metab. 2013, 15:523-530. Gemigliptin Study Group.
29. Sato Y., Hotta K., Hirabayashi Y., Seo N. Anesthesia for cesarean section: a retrospective analysis at the Center for Perinatal and Neonatal Medicine in Jichi Medical University Hospital. Masui 2010, 59:1063-1067.
30. Shirakawa J., Amo K., Ohminami H., Orime K., Togashi Y., Ito Y., Tajima K., Koganei M., Sasaki H., Takeda E., Terauchi Y. Protective effects of dipeptidyl peptidase-4 (DPP-4) inhibitor against increased beta cell apoptosis induced by dietary sucrose and linoleic acid in mice with diabetes. J. Biol. Chem. 2011, 286:25467-25476.
31. Ta N.N., Li Y., Schuyler C.A., Lopes-Virella M.F., Huang Y. DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes. Atherosclerosis 2010, 213:429-435.
32. Tanaka T., Kameoka J., Yaron A., Schlossman S.F., Morimoto C. The costimulatory activity of the CD26 antigen requires dipeptidyl peptidase IV enzymatic activity. Proc. Natl. Acad. Sci. USA 1993, 90:4586-4590.
33. Urano F., Wang X., Bertolotti A., Zhang Y., Chung P., Harding H.P., Ron D. Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1. Science 2000, 287:664-666.
34. Wang D., Luo P., Wang Y., Li W., Wang C., Sun D., Zhang R., Su T., Ma X., Zeng C., Wang H., Ren J., Cao F. Glucagon-like peptide-1 protects against cardiac microvascular injury in diabetes via a cAMP/PKA/Rho-dependent mechanism. Diabetes 2013, 62:1697-1708.
35. Xu Q., Wang J., He J., Zhou M., Adi J., Webster K.A., Yu H. Impaired CXCR4 expression and cell engraftment of bone marrow-derived cells from aged atherogenic mice. Atherosclerosis 2011, 219:92-99.
36. Yang Z.Z., Tschopp O., Baudry A., Dümmler B., Hynx D., Hemmings B.A. Physiological functions of protein kinase B/Akt. Biochem. Soc. Trans. 2004, 32:350-354.
37. Yazbeck R., Howarth G.S., Abbott C.A. Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?. Trends Pharmacol. Sci. 2009, 30:600-607.
38. Zhong J., Rao X., Rajagopalan S. An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular disease. Atherosclerosis 2013, 226:305-314.